Polina Kaplan

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo et al. · New England Journal of Medicine · 2017 · 984 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, Andrzej Pluta, Daniel Lysák et al. · Journal of Clinical Oncology · 2020 · 362 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 347 citations

Pharmacy, Hematology, Pharmacotherapy +5

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 89 citations · Full text

Medicine, Hematology, Pharmacoeconomics +14